Login to Your Account



After long run, Opko moves Rayaldee across the goal

By Marie Powers
News Editor

Tuesday, June 21, 2016

After a long development saga that stretched across multiple companies, Rayaldee was approved by the FDA to treat SHPT in adults with stage 3 or 4 chronic kidney disease who have serum total 25-hydroxyvitamin D levels lower than 30 ng/mL.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription